Trials / Not Yet Recruiting
Not Yet RecruitingNCT07412704
A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
A Phase 1/2a, Open-label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
- Status
- Not Yet Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 84 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the preliminary evidence of disease-modifying effect of BMS-986528 in participants with refractory, difficult-to-treat rheumatoid arthritis (RA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986528 | Specified dose on specified days |
Timeline
- Start date
- 2026-05-28
- Primary completion
- 2029-10-30
- Completion
- 2030-09-02
- First posted
- 2026-02-17
- Last updated
- 2026-02-23
Locations
31 sites across 10 countries: United States, Belgium, China, Germany, Hungary, Italy, Poland, Spain, Switzerland, Ukraine
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07412704. Inclusion in this directory is not an endorsement.